An effective vaccine would be transformative in the fight against the Neisseria gonorrhoeae pathogen ... on its proprietary outer membrane vesicles (OMV) platform technology.

The coveted status is for GSK’s NgG vaccine candidate, currently in a phase 2 trial in adults aged 18 to 50 considered to be at risk from infection with Neisseria ... Avacc 11 OMV-based shot ...

An exploration well drilled offshore Norway by Austrian energy company OMV has turned out to be dry. The Horatio prospect 20 kilometres north-west of the producing Gjoa field in the North Sea was ...

Expert Rev Anti Infect Ther. 2011;9(2):237-244.

At close: March 24 at 5:35:44 PM GMT+1 Loading Chart for OMV.DE ...